Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study.
Sahin TK, Kemik F, Muglu H, Acikgöz Yildiz B, Biter S, Tunbekici S, Oruc A, Guren AK, Kaban K, Guzel HG, Erol C, Aykan MB, Koylu B, Ekinci OB, Deliktas Onur I, Kalem A, Altunok O, Seyyar M, Guney B, Akdogan O, Ismayilov R, Ardic FS, Yazici M, Majidova N, Turker S, Esin E, Cabuk D, Yasar HA, Oguz A, Yazici O, Gursu RU, Yılmaz M, Yesil Cinkir H, Ates O, Celik E, Karadurmus N, Demirci U, Ozturk B, Mandel NM, Bayoglu IV, Araz M, Goker E, Bayram E, Erdem D, Selcukbiricik F, Basaran G, Sezer A, Dogu GG, Kemal Y, Bilici A, Gunduz S, Guven DC, Aksoy S.
Sahin TK, et al. Among authors: ismayilov r.
Ther Adv Med Oncol. 2026 Mar 13;18:17588359261430583. doi: 10.1177/17588359261430583. eCollection 2026.
Ther Adv Med Oncol. 2026.
PMID: 41835339
Free PMC article.